CN105769773B - Loxoprofen sodium sustained-release pellets - Google Patents
Loxoprofen sodium sustained-release pellets Download PDFInfo
- Publication number
- CN105769773B CN105769773B CN201610201063.2A CN201610201063A CN105769773B CN 105769773 B CN105769773 B CN 105769773B CN 201610201063 A CN201610201063 A CN 201610201063A CN 105769773 B CN105769773 B CN 105769773B
- Authority
- CN
- China
- Prior art keywords
- release
- sustained
- loxoprofen sodium
- pellet
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008188 pellet Substances 0.000 title claims abstract description 75
- 238000013268 sustained release Methods 0.000 title claims abstract description 67
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 66
- 229960002373 loxoprofen Drugs 0.000 title claims abstract description 62
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 title claims abstract 17
- 239000003814 drug Substances 0.000 claims abstract description 46
- 229940079593 drug Drugs 0.000 claims abstract description 33
- 239000006187 pill Substances 0.000 claims abstract description 23
- 238000002955 isolation Methods 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 239000011248 coating agent Substances 0.000 claims description 42
- 238000000576 coating method Methods 0.000 claims description 42
- 239000007788 liquid Substances 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 23
- 239000006185 dispersion Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000002775 capsule Substances 0.000 claims description 16
- 239000012153 distilled water Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000001856 Ethyl cellulose Substances 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 229920001249 ethyl cellulose Polymers 0.000 claims description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000007888 film coating Substances 0.000 claims description 4
- 238000009501 film coating Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- -1 polyethylene Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical group CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 229960002510 mandelic acid Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims 8
- 229960003943 hypromellose Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract description 4
- 230000002496 gastric effect Effects 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 46
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000003405 delayed action preparation Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- 229920003157 Eudragit® RL 30 D Polymers 0.000 description 2
- 229920003161 Eudragit® RS 30 D Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 229920003153 Eudragit® NE polymer Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021471 food effect Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960004211 loxoprofen sodium dihydrate Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供一种洛索洛芬钠缓释微丸，它由载药丸芯，包裹于载药丸芯之上的隔离层，以及包裹于隔离层之上的缓释层三部分组成。所述载药丸芯，隔离层以及缓释层的重量比为80∶1～15∶2～20。本发明洛索洛芬钠缓释微丸制剂体外显示良好的释放特性，可减少给药次数，提高患者服药依从性，进而可平稳血药浓度，降低药物胃肠道毒副反应。本发明还公开洛索洛芬钠缓释微丸的制备方法，该方法工艺简单，易于工业化生产。
The invention provides a loxoprofen sodium sustained-release pellet, which is composed of a drug-loaded pill core, an isolation layer wrapped on the drug-loaded pill core, and a sustained-release layer wrapped on the isolation layer. The weight ratio of the drug-loaded pill core, the isolation layer and the slow-release layer is 80:1-15:2-20. The loxoprofen sodium sustained-release pellet preparation of the present invention shows good release characteristics in vitro, can reduce the number of administrations, improve the patient's medication compliance, further stabilize the blood drug concentration, and reduce the gastrointestinal side effects of the drug. The invention also discloses a preparation method of loxoprofen sodium sustained-release pellets, which is simple in process and easy for industrial production.
Description
Technical Field
The invention belongs to the field of pharmacy, and relates to a loxoprofen sodium sustained-release pellet and a preparation method thereof.
Background
Loxoprofen Sodium (Loxoprofen Sodium), the first propionic acid precursor type nonsteroidal anti-inflammatory drugs (NSAIDs), was first developed by japan co. The medicine is metabolized into trans-OH type active medicine in vivo after oral administration, inhibits biosynthesis of prostaglandin, namely covers active center of enzyme by combining with cyclooxygenase, thereby blocking metabolism of arachidonic acid converted into PG by the enzyme, and plays roles of analgesia, antiphlogosis and antipyresis. Loxoprofen sodium as a novel NSAID is a prodrug which is inactive and is active only after rapid conversion by the liver to trans-OH metabolites, unlike other drugs. The analgesic effect is 20 times of that of indometacin, and the mouse paw carrageenin edema experiment shows that the anti-inflammatory effect is twice of that of the indometacin. The medicine has rapid action, and has strong and lasting effects of relieving pain, diminishing inflammation, and relieving fever. At present, the traditional Chinese medicine composition is mainly used for treating rheumatoid arthritis, osteoarthritis, lumbago, scapulohumeral periarthritis, neck, shoulder and wrist syndrome, pains after operation and tooth extraction, acute upper respiratory inflammation and other diseases.
The loxoprofen sodium comprises loxoprofen sodium anhydrous compound, monohydrate or dihydrate, wherein the loxoprofen sodium dihydrate is collected by the Japanese medicine administration and the standards issued by the ministry of China, and is a water-soluble medicine, and the oral preparation of the medicine which is sold on the market at home and abroad at present is mainly loxoprofen sodium tablet, the dosage is 180mg per day, the loxoprofen sodium tablet is taken in three times, and the use convenience is poor. Compared with the common tablets, the loxoprofen sodium sustained-release pellet has the advantages of stabilizing blood concentration, reducing administration times, improving the compliance of patients in taking medicine, reducing gastrointestinal toxic and side effects induced by the over-strong inhibition effect of prostaglandin generated by over-high blood drug peak concentration and the like. In addition, compared with sustained release tablets (unit drug release systems), the loxoprofen sodium sustained release pellets are used as a multi-unit drug delivery system, and 1) after oral administration, the loxoprofen sodium sustained release pellets are rapidly dispersed in the gastrointestinal tract, so that gastric mucosa injury caused by overhigh local concentration is reduced. 2) The micro-pill can easily pass through the gastric pylorus of the human physiological anatomical structure due to the particle size range of less than 1.5mm, thereby avoiding food effect and administration difference among individuals. 3) The multi-unit drug delivery system avoids the occurrence of 'existence' or 'nonexistence' phenomenon existing in the unit drug delivery system, namely the loss of control of individual unit does not influence the drug delivery behavior of the whole system, thereby having higher safety and tolerance.
The polymer aqueous dispersion has been favored in the pharmaceutical industry field for the eighties of the last century because of its environmental protection, low toxicity, low cost, and significant sustained release. The aqueous dispersions currently commercially available for the coating of sustained and controlled release films mainly comprise acrylic resin-based aqueous dispersions (e.g., Eudragit RL30D, Eudragit RS30D, Eudragit NE30) and ethyl cellulose aqueous dispersions (e.g., Surelease and Aquecoat). Wherein the main components of Eudragit RL30D comprise 30% w/w of ethyl acrylate, methyl methacrylate and trimethylammoninylethyl methacrylate in a molar ratio of 1: 2: 0.2, and the main components of Eudragit RS30D comprise 30% w/w of ethyl acrylate, methyl methacrylate and trimethylammoninylethyl methacrylate in a molar ratio of 1: 2: 0.1. Eudragit NE comprises 28.5% w/w of butyl acrylate to methyl methacrylate in a 2: 1 molar ratio and about 1.5% of a stabiliser (nonionic surfactant nonylphenol polyoxyethylene ether 100). The dispersion of the Surilise (Surelease) mainly comprises ethyl cellulose with the solid content of 25%, and also comprises dibutyl sebacate, oleic acid, ammonia water, light silica gel and the like. The aqueous Aqcoat dispersion had a total solids content of 30% and contained 25% w/w ethylcellulose, sodium lauryl sulfate and 5% cetyl alcohol, relative to the weight of the ethylcellulose, 2.7%.
When the water-based dispersion liquid coating is used for preparing the sustained-release pellets, because the surface area of the pellets is larger, a more serious burst release phenomenon often occurs, the invention adopts the process that the isolating layer is firstly coated on the pellet core by the acid isolating liquid, and then the sustained-release layer is coated by the water-based dispersion liquid to prepare the water-based alkaline medicament loxoprofen sodium sustained-release pellets, the burst release phenomenon is reduced, the sustained-release pellets meeting the requirements of the sustained-release preparation are obtained, and the sustained-release pellets are suitable for sustained-release preparations which are administrated 2 times (sustained-release 12h) in 1 day or are administrated once (sustained-release 24.
Disclosure of Invention
The invention provides a loxoprofen sodium-containing sustained-release pellet and a preparation method thereof, the pellet has slow, stable and controllable in-vitro release rate, good reproducibility and simple preparation process, and is easy for industrial production.
The invention aims to provide a loxoprofen sodium sustained-release pellet. The sustained-release pellet comprises a loxoprofen sodium drug-loaded pellet core, an isolation layer coated on the drug-loaded pellet core and a sustained-release layer coated on the isolation layer. Wherein the weight ratio of the drug-loaded pill core to the isolation layer and the slow release layer is 80: 1-15: 2-20.
The loxoprofen sodium sustained-release pellet is characterized in that the particle size of a drug-carrying pellet core is 0.6-1.5 mm. The drug-loaded pill core comprises the following components in percentage by weight:
the drug-loaded pellet core prescription in the loxoprofen sodium sustained-release pellet is characterized in that the adhesive is one or a mixture of two or more of sucrose, dextrin and pregelatinized starch; the wetting agent is selected from one or two mixtures of water and ethanol.
The loxoprofen sodium sustained-release pellet is characterized in that the isolating layer coating solution is an environment-friendly polymer aqueous solution, and the isolating layer coating solution is prepared from the following components in percentage by weight:
the prescription of the isolating layer coating solution in the loxoprofen sodium sustained-release pellet is characterized in that the common film coating material is one or a mixture of two or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol and polyethylene glycol-polyvinyl alcohol block copolymer; the pH regulator is one or a mixture of two or more of citric acid, tartaric acid, succinic acid, fatty acid, malic acid, oxalic acid, glutaric acid, maleic acid, glutamic acid, mandelic acid and fumaric acid; the plasticizer comprises one or two or more of triethyl citrate, glycerol, propylene glycol, polyethylene glycol, phthalate, dibutyl sebacate and diethyl oxalate; the emulsifier is selected from one or two or more of span, tween, lecithin and sodium dodecyl sulfate.
The preparation method of the isolating layer coating solution in the loxoprofen sodium sustained-release pellet is characterized in that the preparation method of the isolating layer coating solution comprises the steps of preparing a solution of a common film coating material by using distilled water, adding a pH regulator, a plasticizer, an emulsifier and talcum powder, fully stirring, uniformly mixing, adding water to a sufficient amount, and preparing the isolating coating solution with the solid content of 5-20%.
The loxoprofen sodium sustained-release pellet is characterized in that the sustained-release coating solution is an environment-friendly polymer aqueous dispersion solution and is selected from one of ethyl cellulose aqueous dispersion solution and acrylic resin aqueous dispersion solution.
The preparation method of the loxoprofen sodium sustained-release pellet is characterized by comprising the following steps of:
(1) preparing loxoprofen sodium pellet cores: weighing loxoprofen sodium, microcrystalline cellulose and an adhesive according to a proportion, uniformly mixing, and preparing a soft material by using a proper amount of wetting agent; extruding the prepared soft material by an extruder to extrude strip-shaped objects; and rolling the obtained strip-shaped object in a rolling machine to obtain a round pill, drying the round pill by using an oven or a fluidized bed, and sieving the round pill by using a sieve with 18-30 meshes to collect the loxoprofen sodium pill core.
(2) Coating an isolation layer: coating the loxoprofen sodium pellet core with an aqueous isolating solution in a fluidized bed or a centrifugal granulator, wherein the product temperature is 30-60 ℃, the liquid inlet speed is 2-40rmp, drying in the fluidized bed or an oven to obtain the pellet coated with the isolating layer,
(3) coating a slow release layer: and (3) coating the pills coated with the isolating layer with a sustained-release aqueous dispersion liquid in a fluidized bed or a centrifugal granulator, wherein the product temperature is 30-80 ℃, the liquid inlet speed is 5-50 rmp, and drying by the fluidized bed or an oven to obtain the loxoprofen sodium sustained-release pellets.
The release rate of the loxoprofen sodium sustained-release pellet mainly depends on the concentration of the pH regulator in the isolation layer, the coating amount of the isolation layer and the coating amount of the sustained-release layer. Experimental research shows that when the amount of the pH regulator accounts for 10-30% of the solid content of the isolation layer, the coating amount of the isolation layer accounts for 5-10% of the weight of the drug-loaded pellet core, and the coating amount of the slow-release layer accounts for 15-20% of the weight of the drug-loaded pellet core, the release degree range of the prepared loxoprofen sodium slow-release pellet with the release medium of water is as follows: 5-30% (2 hours), 40-70% (5 hours) and 70-90% (10 hours).
In conclusion, the loxoprofen sodium sustained-release pellet provided by the invention not only can inhibit the phenomenon of burst release of loxoprofen sodium which is easily dissolved in water, but also can realize good sustained-release drug release characteristics. The preparation process is simple and easy for industrial production.
The research of the loxoprofen sodium sustained-release pellet has great significance, the loxoprofen sodium sustained-release pellet not only reduces the irritation to the gastrointestinal tract, but also reduces the administration times, improves the compliance of patients in taking medicine, and simultaneously slowly releases the medicine at a speed which can not only reach the required blood concentration, but also keep stable, thereby avoiding the side effect of the common tablet caused by the blood peak phenomenon.
Drawings
FIG. 1 shows the release curves of loxoprofen sodium sustained-release pellet capsules provided in examples 1 to 5
Fig. 2 shows the release curve of the loxoprofen sodium sustained-release pellet capsule provided in example 6.
Detailed Description
The invention is further explained or illustrated by the following examples. The examples are only for the purpose of aiding understanding of the present invention, and should not be construed as limiting the spirit and scope of the present invention.
Example 1 loxoprofen sodium sustained release pellet capsule (2000 capsules)
Prescription:
1) medicine-carrying pill core
2) Isolating layer coating liquid
3) Slow-release coating liquid
Stilsilk aqueous dispersion 180g
120g of distilled water
The preparation process comprises the following steps:
1) preparing a drug-loaded pill core: the loxoprofen sodium, the starch and the microcrystalline cellulose are respectively sieved by a sieve of 80 meshes, evenly mixed according to the formula proportion, added with 50 percent ethanol to prepare a soft material, extruded by a sieve plate of an extruder to obtain strips, the strips are put into a spheronizer to be spheronized to obtain round particles, dried for 12 hours at 50 ℃, and sieved by a pellet of 0.6-1.25 mm to obtain the drug-containing pellet core, and the drug-containing pellet core obtained is smooth and clean in appearance, round and high in hardness and is suitable for coating.
2) Preparing an isolating layer coating solution: weighing 130g of HPMC-E5, preparing into solution with distilled water, adding polyethylene glycol 3350, span 80, span 85 and citric acid according to the prescription amount, stirring for dissolving, adding talcum powder according to the prescription amount, stirring uniformly, finally supplementing distilled water to 300g, and stirring uniformly for later use.
3) Preparing a slow-release coating solution: taking the prescribed amount of the Sulisi and the distilled water, and uniformly stirring for later use.
4) Coating the prepared drug-loaded pill core by an isolation layer by adopting a bottom-spraying fluidized bed process, wherein the material temperature is 35-40 ℃, the liquid inlet amount is 15rmp, the liquid spraying pressure is 15-20 bar, and the air blowing amount is 80m3And h, increasing the weight of the isolating layer by 6-9%.
5) Coating the pills with the isolating layer by adopting a bottom-spraying fluidized bed process to form a slow-release layer, wherein the material temperature is 40-45 ℃, the liquid inlet amount is 20rmp, the liquid spraying pressure is 15-20 bar, and the air blowing amount is 80m3And h, increasing the weight of the slow release layer by 16-18%. Drying for 2-12 h at 60 ℃ by a fluidized bed or an oven, taking out and filling into No. 0 capsules.
Example 2 loxoprofen sodium sustained release pellet capsule (2000 capsules)
Prescription:
1) the drug-loaded pellet core is the same as that in example 1
2) Isolating layer coating liquid
3) Slow-release coating liquid
Aqueous dispersion of sulise 240
160g of distilled water
The preparation process comprises the following steps: the same as in example 1.
EXAMPLE 3 loxoprofen sodium sustained-release pellet Capsule (2000 pellets)
Prescription:
1) the drug-loaded pellet core is the same as that in example 1
2) Isolating layer coating liquid
3) Slow-release coating liquid
Stilsilk aqueous dispersion 270g
180g of distilled water
The preparation process comprises the following steps: the same as in example 1.
Example 4 loxoprofen sodium sustained release pellet capsules (2000 capsules)
Prescription:
1) medicine-carrying pill core
2) Isolating layer coating liquid
3) Slow-release coating liquid
Stilsilk aqueous dispersion 270g
180g of distilled water
The preparation process comprises the following steps: the same as in example 1.
Example 5 loxoprofen sodium sustained-release pellet capsules (2000 capsules)
Prescription:
1) medicine carrying pill core: the same as in example 1.
2) Isolating layer coating liquid
3) Slow-release coating liquid
The preparation process comprises the following steps: the process is the same as that of example 1 except that the weight of the coating of the sustained-release layer is increased by 16-19%.
Example 6 loxoprofen sodium sustained release pellet capsules (2000 capsules)
Prescription:
1) medicine-carrying pill core
2) Insulating layer
3) Sustained release layer
Stilsilk aqueous dispersion 270g
Distilled water 180g
The preparation process comprises the following steps: the same as in example 1.
EXAMPLE 7 Release test
The in vitro release rates of the sustained-release pellet capsules prepared in examples 1 to 6 were measured by a dissolution rate measurement method (appendix X C of second part of 2010 edition of chinese pharmacopoeia) paddle method apparatus according to the release rate measurement method (first method XD of appendix of second part of 2010 edition of chinese pharmacopoeia). Taking 900mL of purified water as a medium, rotating at 100 rpm, taking 5mL of solution in 1, 2, 4, 5, 6, 8, 10 and 12h respectively, filtering through a 0.45 μm microporous membrane, and instantly supplementing the medium with the same volume in an operation container. Taking the subsequent filtrate, diluting twice, and respectively measuring absorbance at 223nm wavelength according to spectrophotometry (appendix IV A of second part of the 2010 edition of Chinese pharmacopoeia); taking a proper amount of loxoprofen sodium reference substance, preparing an aqueous solution with the concentration of 30 mu g/mL as a reference substance solution, and measuring the absorbance at the wavelength of 223 nm. The cumulative release was calculated and the results are shown in FIGS. 1 and 2.
From the results of fig. 1 and 2, it can be seen that the drug release of all loxoprofen sodium sustained-release pellet formulations can last for more than 10 hours, and the release rate of the sustained-release pellets in the release medium of water is in the range: 5-30% (2 hours), 40-70% (5 hours) and 70-90% (10 hours), is suitable for 1 day of administration 2 times (sustained release 12 hours) or 1 day of administration once (sustained release 24 hours) sustained release preparation, can avoid the peak valley phenomenon of the drug concentration, reduce the irritation and injury of the drug to the gastrointestinal tract, reduce the administration frequency of the drug, improve the medication compliance of patients, and the preparation method has simple process, good reproducibility, low equipment requirement and easy industrial production.
Claims (6)
1. The loxoprofen sodium sustained-release pellet is characterized by comprising a loxoprofen sodium drug-loaded pellet core, an acidic isolation layer and a sustained-release layer, wherein the acidic isolation layer is wrapped on the drug-loaded pellet core, and the sustained-release layer is wrapped on the acidic isolation layer, and the weight ratio of the drug-loaded pellet core to the acidic isolation layer to the sustained-release layer is 80: 1-15: 2-20; the sustained-release pellet can be directly used as a preparation for oral administration, and can also be filled into an empty capsule for oral administration;
the acidic isolation layer coating solution is an environment-friendly polymer aqueous solution, and the acidic isolation layer coating solution has the following formula in percentage by weight:
the slow release coating liquid is an environment-friendly polymer aqueous dispersion liquid, and is selected from one or a mixture of two of ethyl cellulose aqueous dispersion liquid and acrylic resin aqueous dispersion liquid.
2. The loxoprofen sodium sustained-release pellet as claimed in claim 1, wherein the particle size of the drug-loaded pellet core is 0.6-1.5 mm, and the prescription of the drug-loaded pellet core is as follows by weight percent:
3. the loxoprofen sodium sustained-release pellet core carrying medicine formula in the loxoprofen sodium sustained-release pellet as claimed in claim 2, wherein the adhesive is one or a mixture of two or more of sucrose, dextrin and pregelatinized starch; the wetting agent is selected from one or two mixtures of water and ethanol.
4. The loxoprofen sodium sustained-release pellet as claimed in claim 1, wherein the common film coating material is one or a mixture of two or more of hypromellose, hydroxypropyl cellulose, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol and polyethylene glycol-polyvinyl alcohol block copolymer; the pH regulator is one or a mixture of two or more of citric acid, tartaric acid, succinic acid, fatty acid, malic acid, oxalic acid, glutaric acid, maleic acid, glutamic acid, mandelic acid and fumaric acid; the plasticizer comprises one or two or more of triethyl citrate, glycerol, propylene glycol, polyethylene glycol, phthalate, dibutyl sebacate and diethyl oxalate; the emulsifier is selected from one or two or more of span, tween, lecithin and sodium dodecyl sulfate.
5. The loxoprofen sodium sustained-release pellet as claimed in claim 1, wherein the acidic isolation layer coating solution is prepared by preparing a solution of a common film coating material with distilled water, adding a pH regulator, a plasticizer, an emulsifier and talc powder, stirring thoroughly, mixing well, and adding distilled water to a sufficient amount to prepare an isolation coating solution with a solid content of 5-20%.
6. The loxoprofen sodium sustained-release pellet as claimed in claim 1, wherein the preparation method comprises the following steps:
(1) preparing loxoprofen sodium pellet cores: weighing loxoprofen sodium, microcrystalline cellulose and an adhesive according to a proportion, uniformly mixing, and preparing a soft material by using a proper amount of wetting agent; extruding the prepared soft material by an extruder to extrude strip-shaped objects; rounding the obtained strip-shaped object in a rounding machine to obtain a round pill, drying the round pill by an oven or a fluidized bed, and sieving the round pill by a sieve with 18-30 meshes to collect a loxoprofen sodium pill core;
(2) coating an acid isolation layer: coating the loxoprofen sodium pellet core with an aqueous acidic isolating solution in a fluidized bed or a centrifugal granulator, wherein the product temperature is 30-60 ℃, the liquid inlet speed is 2-40rmp, and drying in the fluidized bed or an oven to obtain pellets coated with the isolating layer;
(3) coating a slow release layer: and (3) coating the pills coated with the isolating layer with a sustained-release aqueous dispersion liquid in a fluidized bed or a centrifugal granulator, wherein the product temperature is 30-80 ℃, the liquid inlet speed is 5-50 rmp, and drying by the fluidized bed or an oven to obtain the loxoprofen sodium sustained-release pellets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610201063.2A CN105769773B (en) | 2016-03-30 | 2016-03-30 | Loxoprofen sodium sustained-release pellets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610201063.2A CN105769773B (en) | 2016-03-30 | 2016-03-30 | Loxoprofen sodium sustained-release pellets |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105769773A CN105769773A (en) | 2016-07-20 |
| CN105769773B true CN105769773B (en) | 2021-05-14 |
Family
ID=56394537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610201063.2A Active CN105769773B (en) | 2016-03-30 | 2016-03-30 | Loxoprofen sodium sustained-release pellets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105769773B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113750077B (en) * | 2021-10-16 | 2022-12-20 | 河南省人民医院 | Amlodipine besylate sustained-release pellet and preparation method thereof |
| CN114983973B (en) * | 2022-05-31 | 2023-05-05 | 石家庄四药有限公司 | Urapidil sustained-release capsule and preparation method thereof |
| CN116650444B (en) * | 2023-07-31 | 2023-10-31 | 国药集团川抗制药有限公司 | Tacrolimus slow-release drug and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1628648A (en) * | 2004-08-26 | 2005-06-22 | 复旦大学 | Loxoprofen Sodium Sustained Release Preparation |
| CN101489536A (en) * | 2006-07-19 | 2009-07-22 | 旭化成化学株式会社 | Process for producing spherical elementary granule containing readily water-soluble drug |
| CN102525989A (en) * | 2011-01-04 | 2012-07-04 | 北京天衡药物研究院 | Loxoprofen sodium matrix sustained-release tablet |
| JP2014111565A (en) * | 2012-11-09 | 2014-06-19 | Taisho Pharmaceutical Co Ltd | Pharmaceutical composition |
-
2016
- 2016-03-30 CN CN201610201063.2A patent/CN105769773B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1628648A (en) * | 2004-08-26 | 2005-06-22 | 复旦大学 | Loxoprofen Sodium Sustained Release Preparation |
| CN101489536A (en) * | 2006-07-19 | 2009-07-22 | 旭化成化学株式会社 | Process for producing spherical elementary granule containing readily water-soluble drug |
| CN102525989A (en) * | 2011-01-04 | 2012-07-04 | 北京天衡药物研究院 | Loxoprofen sodium matrix sustained-release tablet |
| JP2014111565A (en) * | 2012-11-09 | 2014-06-19 | Taisho Pharmaceutical Co Ltd | Pharmaceutical composition |
Non-Patent Citations (1)
| Title |
|---|
| 离心造粒法制备洛索洛芬钠缓释微丸及体外释放度考察;陈云;《中国药师》;20110131;第14卷(第11期);第84页"摘要"和"1 仪器与试药"，第85页"2.3"和"2.4" * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105769773A (en) | 2016-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2492854C2 (en) | Production of rapidly dissolved/short lived films containing large number of active substances | |
| CN1356102A (en) | Taste Masked medicine particles | |
| HU186538B (en) | Process for producing retarde pharmaceutical compositions containing bromohexine | |
| AU2011350396A1 (en) | Orally disintegrating tablet | |
| CN101528205A (en) | Ibuprofen composition | |
| EP2754438B2 (en) | Coating composition, drug-containing particle, solid preparation and method for preparing drug-containing particle | |
| US20120251588A1 (en) | Coating Composition, Solid Preparation Coated Therewith, and Method for Preparing Solid Preparation | |
| WO2013139209A1 (en) | Topiramate sustained-release pharmaceutical composition, method for preparing same, and use thereof | |
| JP5881700B2 (en) | Blonanserin oral release controlled pharmaceutical composition | |
| CN105769773B (en) | Loxoprofen sodium sustained-release pellets | |
| EP3445360B1 (en) | Oral pharmaceutical compositions of nicotinamide | |
| CN105055350B (en) | A kind of preparation method of the tablet containing proton pump inhibitor | |
| CN101411702B (en) | Nefopam hydrochloride naproxen sodium compound sustained-release preparation and preparation method thereof | |
| CN101259150A (en) | Sustained-release pellets of ginkgo biloba extract and preparation method thereof | |
| CN109646417B (en) | Trimetazidine sustained release tablet and preparation method thereof | |
| RU2727721C2 (en) | Sustained-release pharmaceutical composition containing rivastigmine | |
| CN101095663A (en) | Nicergoline sustained-release capsules and preparation method thereof | |
| CN101829070A (en) | Clarithromycin slow-release dispersible tablets and preparation method thereof | |
| EP3331502A1 (en) | Controlled release propiverine formulations | |
| CN101658507B (en) | Glyceryl guaiacolate and pseudoephedrine compound sustained release preparation | |
| CN109833299B (en) | Micronized roxatidine acetate medicinal salt pellet as well as preparation method and application thereof | |
| CN109833306B (en) | Roxatidine acetate medicinal salt sustained-release pellet as well as preparation method and application thereof | |
| CN104473895A (en) | Lamotrigine orally disintegrating sustained release tablets | |
| CN108553416A (en) | A kind of sustained release mixed suspension preparation and preparation method thereof containing levodopa and benserazide hydrochloride | |
| CN114432257B (en) | Bluprofen sustained-release tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |